我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

iPSCs在心律失常疾病体外模型方面的研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第6期
页码:
711-715
栏目:
综述
出版日期:
2013-11-25

文章信息/Info

Title:
Research progress of induced pluripotent stem cells in in vitro models of arrhythmogenic diseases
作者:
种朝阳臧伟进周 筠
(西安交通大学医学院药理学系,陕西 西安 710061)
Author(s):
CHONG Zhao yang ZANG Wei jin ZHOU Jun
(Department of Pharmacology, College of Medicine, Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China)
关键词:
心律失常诱导型多能干细胞体外模型
Keywords:
arrhythmia induced pluripotent stem cells in vitro model
分类号:
R541.7
DOI:
-
文献标识码:
A
摘要:
心律失常严重威胁人类健康,许多遗传性心律失常由基因突变引起。以患者的诱导型多能干细胞(iPSCs)源性的心肌细胞作为体外模型,可为研究心律失常的发病机制提供新的思路。本文主要对iPSCs源性诱导型心肌细胞的产生过程以及心律失常患者诱导iPSCs心肌细胞在长QT综合征、儿茶酚胺依赖性室性心动过速、致心律失常性右室心肌病等疾病模型的研究进展进行了综述。
Abstract:
Arrhythmogenic diseases can be life threatening. Many genetic arrhythmias are caused by gene mutations. As an in vitro model to study hereditary arrhythmogenic diseases, induced pluripotent stem cellderived cardiomyocytes (iPSC-CMs) are induced by somatic cells obtained from patients, offering new insight into the study of arrhythmia pathogenesis.This paper mainly reviews the generation process of the induced cardiomyocytes from iPSCs and the iPS models of arrhythmogenic diseases including long QT syndrome, catecholaminedependent ventricular tachycardia and arrhythmogenic right ventricular cardiomyopathy.

参考文献/References

[1]Takahashi K,Tanabe K,Ohnuki M,et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors[J].Cell,2007,131(5):86l-872.
[2]YU J,Vodyanik MA,Smuga otto K,et al.Induced pluripotent stem cell lines derived from human somatic cells[J].Science,2007,318(5858):1917-1920.
[3]Yu J,Hu K,SmugaOtto K,et al.Human induced pluripotent stem cells free of vector and transgene sequences[J].Science,2009,324(5928):797-801.
[4]Kim D,Kim CH,Moon JI,et al.Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins[J].Cell Stem Cell,2009,4(6):472-476.
[5]Warren L,Ni Y,Wang J,et al.Feederfree derivation of human induced pluripotent stem cells with messenger RNA[J].Sci Rep,2012,2:657.
[6]Oh Y,Wei H,Ma D,et al.Clinical applications of patientspecific induced pluripotent stem cells in cardiovascular medicine[J].Heart,2012,98(6):443-449.
[7]Burridge PW,Anderson D,Priddle H,et al.Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V96 plate aggregation system highlights interline variability[J].Stem cells,2007,25(4):929-938.
[8]Kawaguchi N,Hayama E,Furutani Y,et al.Prospective in vitro models of channelopathies and cardiomyopathies[J].Stem Cells Int,2012,2012:439219.
[9]Xi J,Khalil M,Shishechian N,et al.Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells[J].FASEB J,2010,24(8):2739-2751.
[10]Moretti A,Bellin M,Welling A,et al. Patientspecific induced pluripotent stemcell models for longQT Syndrome[J]. New Engl J Med,2010,363(15):1397-1409.
[11]Itzhaki I,Maizels L,Huber I,et al.Modelling the long QT syndrome with induced pluripotent stem cells[J].Nature,2011,471(7337):225-229.
[12]Matsa E,Rajamohan D,Dick E,et al.Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation[J].Eur Heart J,2011,32(8): 952-962.
[13]Lahti AL,Kujala VJ,Chapman H,et al.Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture[J].Dis Model Mech,2012,5(2):220-230.
[14]Yazawa M,Hsueh B,Jia X,et al.Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome[J].Nature,2011,471(7337):230-234.
[15]Kujala K,Paavola J,Lahti A,et al.Cell model of Catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations[J].Plos One,2012,7(9):e44660.
[16]ung CB,Moretti A,Mederos y Schnitzler M,et al.Dantrolene rescues arrhythmogenic RYR2 defect in a patientspecific stem cell model of catecholaminergic polymorphic ventricular tachycardia[J].EMBO Mol Med,2012,4(3):180-191.
[17]Ma D,Wei H,Lu J,et al.Generation of patientspecific induced pluripotent stem cellderived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy[J].Eur Heart J,2013,34(15):1122-1133.
[18]Cao N,Liu Z,Chen Z,et al.Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells[J].Cell Res,2012,22(1):219-236.
[19]Sheng X,Reppel M,Nguemo F,et al.Human pluripotent stem cellderived cardiomyocytes: response to TTX and lidocain reveals strong cell to cell variability[J].Plos One,2012,7(9):e45963.

备注/Memo

备注/Memo:
收稿日期: 2013-03-29.基金项目:国家自然科学基金项目资助(81170176);教育部留学回国人员科研启动基金项目资助(12回国基金08);国家自然科学基金重大国际(地区)合作项目资助(81120108002) 通讯作者:周筠,副教授,主要从事心血管药理学研究 Email:jzhou829@yahoo.com.cn 作者简介:种朝阳,硕士生 Email:chongzhaoyang@163.com
更新日期/Last Update: 2013-11-20